MONTRÉAL, Québec, Canada — November 2, 2026 — When a new disease emerges, a rapid response can save lives. That is why NRC researchers are developing versatile, “ready-to-use” vaccine components that can be deployed as new health threats arise.
The SLA adjuvant is one example: it can be used in a variety of vaccines to enhance immune responses.
Now manufactured and marketed by Glycovax Pharma, SLA is also included in the world’s first adjuvant library—an international resource that gives vaccine developers faster access to proven tools, shortening the path from discovery to protection.
Glycovax will use the SLA adjuvant to develop its own vaccines and will also manufacture it for other vaccine developers.
Posted in News